Harvard Bioscience (NASDAQ:HBIO) Shares Cross Below 200-Day Moving Average – Should You Sell?

Harvard Bioscience, Inc. (NASDAQ:HBIO) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.58 and traded as low as $1.93. Harvard Bioscience shares last traded at $1.98, with a volume of 83,714 shares changing hands.

Harvard Bioscience Trading Up 0.5 %

The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.91. The stock’s 50-day moving average is $2.15 and its two-hundred day moving average is $2.56. The company has a market cap of $84.19 million, a P/E ratio of -5.85 and a beta of 1.27.

Hedge Funds Weigh In On Harvard Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in shares of Harvard Bioscience by 63.0% in the third quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock worth $79,000 after acquiring an additional 11,397 shares during the period. Barclays PLC grew its stake in shares of Harvard Bioscience by 304.4% during the 3rd quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier’s stock valued at $157,000 after purchasing an additional 44,150 shares during the period. Geode Capital Management LLC increased its position in shares of Harvard Bioscience by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock valued at $2,455,000 after purchasing an additional 19,972 shares during the last quarter. State Street Corp increased its position in shares of Harvard Bioscience by 1.1% during the 3rd quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock valued at $1,930,000 after purchasing an additional 7,763 shares during the last quarter. Finally, Harvey Partners LLC lifted its stake in shares of Harvard Bioscience by 6.2% in the 3rd quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock worth $7,303,000 after purchasing an additional 157,500 shares during the period. 80.87% of the stock is owned by institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.